Evaluation of antenatal risk factors for postpartum depression: a secondary cohort analysis of the cluster-randomised GeliS trial

Johar, Hamimatunnisa; Hoffmann, Julia; Günther, Julia; Atasoy, Seryan; Stecher, Lynne; Spies, Monika; Hauner, Hans; Ladwig, Karl‐Heinz

doi:10.1186/s12916-020-01679-7

Cited by 21 publications

(16 citation statements)

References 52 publications

(77 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effects of maternal obesity on pregnancy and child health have been extensively studied, and systematic evaluations have found an increased incidence of pregnancy complications in pregnancy, including gestational diabetes ( 21 ), preeclampsia ( 22 ), hypertension, depression ( 23 ), cesarean section, preterm delivery, surgical site infections, and neonatal complications including perinatal death ( 24 ), macrosomia ( 25 ), and fetal defects. The impact of paternal obesity on pregnancy and child health has received less attention.…”

Section: Discussionmentioning

confidence: 99%

Effects of Paternal Obesity on Fetal Development and Pregnancy Complications: A Prospective Clinical Cohort Study

Lin

Huang

2022

Front. Endocrinol.

View full text Add to dashboard Cite

ObjectivesTo evaluate the association between paternal obesity and fetal development and pregnancy complications.Study DesignThis prospective cohort clinical trial analyzed data from 7683 women with singleton pregnancies. All study subjects were sequentially divided into four groups based on paternal BMI. We compared the differences in fetal growth and pregnancy complications between different paternal BMI groups by univariate logistic regression and independent t-test. Finally, the independent predictors of SGA and macrosomia were determined.ResultsThe incidences of preeclampsia, cesarean section, SGA, macrosomia, and postpartum hemorrhage in the paternal obesity group were significantly higher than the normal BMI group. With the increase of paternal BMI, fetal ultrasound measurement parameter, neonatal and placental weight showed an increasing trend (trend P < 0.05). However, these differences disappeared in the obese group. The test for interaction showed the effect of paternal obesity on SGA and macrosomia was significantly affected by maternal obesity. We also found paternal obesity was an independent predictor of both SGA and macrosomia. Based on the above results, we plotted the Nomograms for clinical prediction.ConclusionPaternal obesity can affect fetal growth parameters and placental development, which has an adverse impact on pregnancy outcomes. Optimizing the paternal BMI will help improve the health of the next generation.

show abstract

Section: Discussionmentioning

confidence: 99%

Effects of Paternal Obesity on Fetal Development and Pregnancy Complications: A Prospective Clinical Cohort Study

Lin

Huang

2022

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…The primary goal of the GeliS study was to reduce the proportion of women with excessive GWG according to the IOM criteria [ 5 ] through a comprehensive lifestyle intervention programme alongside routine care visits. Results on primary and secondary endpoints have already been published [ 8 , 39 , 40 , 41 , 42 , 43 , 44 , 45 ]. This secondary analysis focuses on the effect of the GeliS lifestyle intervention programme on maternal health behaviour during the first 12 months postpartum.…”

Section: Methodsmentioning

confidence: 99%

Effects of a Prenatal Lifestyle Intervention in Routine Care on Maternal Health Behaviour in the First Year Postpartum—Secondary Findings of the Cluster-Randomised GeliS Trial

et al. 2021

Self Cite

View full text Add to dashboard Cite

Lifestyle interventions during pregnancy were shown to beneficially influence maternal dietary behaviour and physical activity, but their effect on health behaviour after delivery is unclear. The objective of this secondary analysis was to investigate the sustained effect of a lifestyle intervention in routine care on maternal health behaviour during the first year postpartum. The cluster-randomised controlled “Healthy living in pregnancy” (GeliS) study included 2286 pregnant women. Data on maternal health behaviour were collected at 6–8 weeks (T1pp) and one year postpartum (T2pp) using validated questionnaires. The intervention group showed a lower mean intake of fast food (T1pp: p = 0.016; T2pp: p < 0.001) and soft drinks (T1pp: p < 0.001), a higher mean intake of vegetables (T2pp: p = 0.015) and was more likely to use healthy oils for meal preparation than the control group. Dietary quality rated by a healthy eating index was higher in the intervention group (T1pp: p = 0.093; T2pp: p = 0.043). There were minor trends towards an intervention effect on physical activity behaviour. The proportion of smokers was lower in the intervention group (p < 0.001, both time points). The lifestyle intervention within routine care modestly improved maternal postpartum dietary and smoking behaviours.

show abstract

“…Interestingly, EPM301 has shown impressive results in treating neuro-behavioral conditions such as anxiety and nausea, demonstrating efficacy at lower doses compared to CBDA [ 28 ], and major depression [ 29 ]. Accordingly, depression was linked to obesity in different studies [ 30 , 31 , 32 , 33 ]. Hence, an intriguing question is whether EPM301 can be used to treat DIO and GIO.…”

Section: Introductionmentioning

confidence: 99%

The Metabolic Efficacy of a Cannabidiolic Acid (CBDA) Derivative in Treating Diet- and Genetic-Induced Obesity

Ben-Cnaan

Permyakova

Azar

et al. 2022

IJMS

View full text Add to dashboard Cite

Obesity is a global medical problem; its common form is known as diet-induced obesity (DIO); however, there are several rare genetic disorders, such as Prader–Willi syndrome (PWS), that are also associated with obesity (genetic-induced obesity, GIO). The currently available therapeutics for treating DIO and GIO are very limited, and they result in only a partial improvement. Cannabidiolic acid (CBDA), a constituent of Cannabis sativa, gradually decarboxylates to cannabidiol (CBD). Whereas the anti-obesity properties of CBD have been reasonably identified, our knowledge of the pharmacology of CBDA is more limited due to its instability. To stabilize CBDA, a new derivative, CBDA-O-methyl ester (HU-580, EPM301), was synthesized. The therapeutic potential of EPM301 in appetite reduction, weight loss, and metabolic improvements in DIO and GIO was tested in vivo. EPM301 (40 mg/kg/d, i.p.) successfully resulted in weight loss, increased ambulation, as well as improved glycemic and lipid profiles in DIO mice. Additionally, EPM301 ameliorated DIO-induced hepatic dysfunction and steatosis. Importantly, EPM301 (20 and 40 mg/kg/d, i.p.) effectively reduced body weight and hyperphagia in a high-fat diet-fed Magel2null mouse model for PWS. In addition, when given to standard-diet-fed Magel2null mice as a preventive treatment, EPM301 completely inhibited weight gain and adiposity. Lastly, EPM301 increased the oxidation of different nutrients in each strain. All together, EPM301 ameliorated obesity and its metabolic abnormalities in both DIO and GIO. These results support the idea to further promote this synthetic CBDA derivative toward clinical evaluation in humans.

show abstract

Evaluation of antenatal risk factors for postpartum depression: a secondary cohort analysis of the cluster-randomised GeliS trial

Cited by 21 publications

References 52 publications

Effects of Paternal Obesity on Fetal Development and Pregnancy Complications: A Prospective Clinical Cohort Study

Effects of Paternal Obesity on Fetal Development and Pregnancy Complications: A Prospective Clinical Cohort Study

Effects of a Prenatal Lifestyle Intervention in Routine Care on Maternal Health Behaviour in the First Year Postpartum—Secondary Findings of the Cluster-Randomised GeliS Trial

The Metabolic Efficacy of a Cannabidiolic Acid (CBDA) Derivative in Treating Diet- and Genetic-Induced Obesity

Contact Info

Product

Resources

About